Ideaya Biosciences Enrolls First Patient In Its Phase 1 Trial Of IDE892 In Combination With IDE397 In Mtap-deleted Pancreatic And Lung Cancers
IDEAYA Biosciences
IDEAYA Biosciences IDYA | 0.00 |
- IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS inhibitors, with favorable drug-like properties
- IDE892 has a CYP3A4 IC50 greater than 45 micromolar, and did not show time dependent inhibition of any of the 7 major cytochrome P450s (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4) based on full kinetic CYP inactivation assays
- IDE892 monotherapy Phase 1 escalation has cleared multiple dose cohorts with maximally efficacious target exposures anticipated at a favorable pill size and the MTD has not yet been reached. IDE892 monotherapy expansion is anticipated in Q3 2026
- MTAP-deletion is estimated to occur in up to 40% of pancreatic cancer and ~15% of non-small cell lung cancer (NSCLC)